Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010;10:514–23.

CAS  PubMed  Article  Google Scholar 

Josephs DH, Sarker D. Pharmacodynamic biomarker development for PI3K pathway therapeutics. Transl Oncogenom. 2015;7:33–49.

CAS  Google Scholar 

Dixon WJ, Mood AM. The statistical sign test. J Am Stat Assoc. 1946;41:557–66.

CAS  PubMed  Article  Google Scholar 

Kurzrock R, Lin CC, Wu TC, Hobbs BP, Pestana RC, Hong DS. Moving beyond 3+3: the future of clinical trial design. Am Soc Clin Oncol Educ Book. 2021;41:e133–44.

PubMed  Article  Google Scholar 

Araujo DV, Oliva M, Li K, Fazelzad R, Liu ZA, Siu LL. Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era. Eur J Cancer. 2021;158:85–98.

CAS  PubMed  Article  Google Scholar 

Saxena A, Rubens M, Ramamoorthy V, Zhang Z, Ahmed MA, McGranaghan P, et al. A brief overview of adaptive designs for phase I cancer trials. Cancers. 2022;14:1566.

PubMed  PubMed Central  Article  Google Scholar 

Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer. 2008;44:19–24.

CAS  PubMed  Article  Google Scholar 

Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst. 2004;96:990–7.

CAS  PubMed  Article  Google Scholar 

Iasonos A, Gönen M, Bosl GJ. Scientific review of phase I protocols with novel dose-escalation designs: how much information is needed? J Clin Oncol. 2015;33:2221–5.

PubMed  PubMed Central  Article  Google Scholar 

U.S. Food and Drug Administration. Guidance for Industry, Clinical Considerations for Therapeutic Cancer Vaccines. 2011. https://www.fda.gov/media/82312/download.

Chiuzan C, Shtaynberger J, Manji GA, Duong JK, Schwartz GK, Ivanova A, et al. Dose-finding designs for trials of molecularly targeted agents and immunotherapies. J Biopharm Stat. 2017;27:477–94.

PubMed  PubMed Central  Article  Google Scholar 

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.

CAS  PubMed  Article  Google Scholar 

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–80.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM, Wagner-Johnston ND, et al.CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-Kinase P110d, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia.Blood. 2010;116:55.

Article  Google Scholar 

Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood. 2010;115:4497–506.

CAS  PubMed  Article  Google Scholar 

Herman SE, Niemann CU, Farooqui M, Jones J, Mustafa RZ, Lipsky A, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28:2188–96.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–7.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Barrientos JC, Burger JA, Byrd JC, Hillmen P, Zhou C, Ninomoto J, et al. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019;60:1000–5.

CAS  PubMed  Article  Google Scholar 

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787–98.

CAS  PubMed  Article  Google Scholar 

Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.

CAS  PubMed  Article  Google Scholar 

de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect. 2015;3:e00156.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278–91.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ghia P, Pluda A, Wach M, Lysak D, Kozak T, Simkovic M, et al. Acalabrutinib vs idelalisib plus rituximab (IDR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results. EHA Libr. 2020;294979:S159.

Google Scholar 

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397:892–901.

CAS  PubMed  Article  Google Scholar 

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–7.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Flinn IW, O’Brien S, Kahl B, Patel M, Oki Y, Foss FF, et al. Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies. Blood. 2018;131:877–87.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446–55.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zydelig (idelalisib) [package insert]. Gilead Science, Inc.; 2018.

Copiktra (duvelisib) [package insert]. Verastem, Inc.; 2018.

Burris HA III, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, et al. Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018;19:486–96.

CAS  PubMed  Article  Google Scholar 

Richardson NC, Kasamon Y, Pazdur R, Gormley N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 2022;23:563–6.

CAS  PubMed  Article  Google Scholar 

TG Therapeutics. TG Therapeutics announces voluntary withdrawal of the BLA/sNDA for U2 to treat patients with CLL and SLL. 2022. https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-voluntary-withdrawal-blasnda-u2-treat.

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–22.

CAS  PubMed  Article  Google Scholar 

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107–20.

CAS  PubMed  Article  Google Scholar 

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225–36.

CAS  PubMed  Article  Google Scholar 

Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010;16:1289–97.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018;132:2249–59.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ahn IE, Basumallik N, Tian X, Soto S, Wiestner A. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood. 2019;133:2452–5.